Verona Pharma plc

NasdaqGM VRNA

Verona Pharma plc Operating Income for the year ending December 31, 2023: USD -67.83 M

Verona Pharma plc Operating Income is USD -67.83 M for the year ending December 31, 2023, a -2.59% change year over year. Operating income is the profit earned by a company from its normal business operations before interest and taxes are deducted.

Verona Pharma plc Operating Income for the year ending December 31, 2022 was USD -66.12 M, a 9.82% change year over year.
Verona Pharma plc Operating Income for the year ending December 31, 2021 was USD -73.31 M, a 1.30% change year over year.
Verona Pharma plc Operating Income for the year ending December 31, 2020 was USD -74.28 M, a -4.07% change year over year.
Verona Pharma plc Operating Income for the year ending December 31, 2019 was USD -71.37 M, a -72.54% change year over year.

Key data

Date	Operating Income	EBIT	EBITDA	Net Income

NasdaqGM: VRNA

Verona Pharma plc

CEO	Dr. David S. Zaccardelli Pharm.D.
IPO Date	April 28, 2017
Location	United Kingdom
Headquarters	3 More London Riverside
Employees	79
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials Composite Materials Pollution Treatment

Description

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

Key trends

Past 5 years